Lesson 6 Review Organoids

Applied Molecular Cellular Biology

🌟 What Are Organoids?

  • Organoids = tiny, 3D “mini-organs” grown in the lab.
  • Built from stem cells that self-organize into tissue-like structures.
  • Two main flavors:
    1. PSC-derived (pluripotent stem cells): mimic embryonic development. Good for studying how organs form 🧠🫁.
    2. ASC-derived (adult stem cells): mimic tissue repair. Great for modeling adult organs and diseases 🧑‍⚕️.

🔬 How Do They Compare to Older Models?

  • 2D cell lines: cheap and simple, but often mutated, lack diversity, and don’t mimic real tissue well.
  • Patient-derived xenografts (PDXs): human tumors transplanted into mice. Better than 2D, but slow, costly, and tricky.
  • Organoids: faster, more faithful, expandable, and usable from both healthy and diseased tissue. ✅

🧩 Building Organoids

  • Need extracellular matrix support (often Matrigel).
  • Use specific growth factor cocktails (e.g., Wnt, R-spondin, EGF, Noggin).
  • PSC-organoids = long protocols (months), complex tissues.
  • ASC-organoids = faster (days to weeks), stable, expandable long term.

🏥 Applications of Organoids

1. Studying Physiology 🧬

  • Organoids allow culture of previously impossible cell types (e.g., hepatocytes that make albumin + detox enzymes).
  • Reveal mechanisms like BMP gradients controlling gut hormone expression.

2. Modeling Diseases 🦠🧑‍⚕️

  • Infectious disease:
    • Cryptosporidium life cycle in gut organoids 💩
    • Helicobacter pylori in stomach organoids 🍲
    • Norovirus replication only works in intestinal organoids 🚽
    • RSV infection in airway organoids → syncytia + neutrophil attraction 🫁
    • Influenza strains tested for infectivity 🦠
  • Genetic diseases:
    • Cystic fibrosis → organoids swell in forskolin assay only if CFTR works. Used to test drugs + CRISPR repair 💨
    • Alagille syndrome, α1-antitrypsin deficiency, microvillus inclusion disease, etc. modeled.
  • Cancer:
    • Tumor-derived organoids capture heterogeneity 🎭
    • CRISPR-engineered normal organoids can model stepwise mutations (e.g., APC, KRAS, TP53).
    • Used to study metastasis, drug resistance, DNA repair failures.

📦 Organoid Biobanks

  • Living libraries of organoids from patients.
  • Cover colon, pancreas, liver, prostate, breast, ovary, bladder, etc.
  • Store both tumor and matched normal tissue → great for drug testing and biology.
  • Example: breast cancer biobank retained hormone receptor status (ER/PR/HER2).
  • Drug responses in organoids often mirror patient responses (e.g., pancreatic, ovarian, GI cancers). 🔑 for personalized therapy.

🧑‍⚕️ Organoids in Medicine

Genetic Repair

  • CRISPR correction in cystic fibrosis organoids restored function 🛠️.

Transplantation

  • Mouse studies show transplanted colon or liver organoids can integrate and restore function (colitis, liver failure) 🐭➡️❤️.

Immunotherapy

  • Organoids cocultured with immune cells help study tumor–immune interactions ⚔️.
  • Tumor organoids used to activate patient T cells → potential personalized immunotherapy.

Cystic Fibrosis in the Netherlands

  • First clinical use: forskolin swelling assay determines which drugs work for each patient.
  • Therapy choices (like Kalydeco, Orkambi) now guided by organoid response instead of just genotype. 🚀

⚠️ Limitations

  • Dependence on animal-based matrices (Matrigel) 🐭.
  • High cost 💰.
  • Lack of full tissue complexity (no blood vessels, immune cells, or nerves).
  • Some cancers/tissues still hard to grow.

🔮 Future Perspectives

  • Expand to hard-to-culture cancers (sarcomas, melanomas).
  • Develop synthetic, defined culture systems.
  • Use for rare genetic diseases with no large clinical trials.
  • Scale up for regenerative medicine and personalized drug screening. 🌍

✨ Key Takeaways

  1. Organoids are 3D mini-organs from PSCs (development) or ASCs (repair).
  2. They’re genetically stable, expandable, and versatile.
  3. Useful for modeling infections, genetic diseases, cancers, and physiology.
  4. Biobanks + CRISPR + drug screens make them powerful for personalized medicine.
  5. Already clinically applied in cystic fibrosis treatment decisions.
  6. Challenges: cost, lack of non-epithelial components, reliance on animal matrices.

Quiz

Score: 0/30 (0%)